Phaseline

Companies › Orbus Therapeutics

Orbus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 8 registered trials: 3 Phase 1, 3 Phase 2, 1 Phase 4, 1 Phase 3; Immunology, Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eflornithine
Ornithine decarboxylase inhibitor
ODC1Phase 1Glioblastoma, IDH-wildtype; Hirsuitism; Colorectal Neoplasms; Prostate Cancer …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06976424EflornithinePhase 4HirsuitismImmunologyDec 2025
NCT05879367EflornithinePhase 1Glioblastoma, IDH-wildtypeOncologyJun 2026
NCT06059118EflornithinePhase 2Prostate CancerOncologyJan 2027
NCT01349881EflornithinePhase 3Colorectal NeoplasmsOncologySep 2027
NCT03794349EflornithinePhase 2High Risk NeuroblastomaOncologyMar 2029
NCT07468136EflornithinePhase 1Anaplastic OligodendrogliomaOncologyOct 2030
NCT07321912EflornithinePhase 2OsteosarcomaOncologyJun 2031
NCT06465199EflornithinePhase 1Atypical Teratoid/Rhabdoid TumorOncologyMay 2033

Targets

ODC1 (1)

Companies with the same targets

Aminex Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.